Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
J Allergy Clin Immunol. 2012 Sep;130(3):563-71. doi: 10.1016/j.jaci.2012.07.027.
Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders.
高嗜酸性粒细胞综合征（HES）是一组表现为嗜酸性粒细胞增多和嗜酸性粒细胞浸润组织的临床表现的疾病。HES 是一种慢性疾病，具有显著的发病率和死亡率。虽然靶向化疗药物的出现，包括伊马替尼，已经改善了一些 HES 患者的生活质量和生存率，但仍然迫切需要具有更高疗效和更低毒性的其他药物。本综述的目的是提供对嗜酸性粒细胞生物学的概述，重点介绍潜在的药物治疗靶点，并对潜在的嗜酸性粒细胞靶向药物进行总结，包括正在开发、临床试验或批准用于其他疾病的药物。
